Mateon Therapeutics (MATN) Announces Receipt of Cathepsin-Related U.S. Patent

October 10, 2016 8:35 AM EDT
Get Alerts MATN Hot Sheet
Trade MATN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Mateon Therapeutics, Inc. (Nasdaq: MATN) announced that the U.S. Patent and Trademark Office has issued U.S. Patent 9,458,103 to Mateon and Baylor University for “Compositions and methods for inhibition of cathepsins.” The patent covers compounds which modulate cathepsin activity, particularly cathepsin L or cathepsin K, and methods of using these compounds for the treatment of conditions in which their regulation may be therapeutically useful.

“I am pleased to have this patent issued,” stated William D. Schwieterman, M.D., President and Chief Executive Officer of Mateon. “For the past few years we have been working with Baylor University to pursue discovery and development of novel, small-molecule therapeutics that may be effective in oncology indications, and we are continuing several interesting, early-stage opportunities in this field.”

Cathepsins have been validated as an important enzymatic class to target in drug discovery research, and eleven cysteine protease cathepsin enzymes have been identified to date in humans, with different structures and functions. Cathepsin L has a function in the growth and metastasis of primary tumors and has been implicated in diabetes, immunological responses, degradation of the articular cartilage matrix, and other pathological processes, including osteoporosis and rheumatoid arthritis. Inhibition of cathepsin L has also been shown to block Severe Acute Respiratory Syndrome (SARS) and Ebola pseudotype virus infection. Cathepsin K plays a role in bone resorption and has implications in osteoporosis.

About MateonMateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes VDAs such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.

At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.

Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation, Management Comments

Add Your Comment